Kathleen Neuzil

Last updated
Kathleen Maletic Neuzil
Alma mater University of Maryland, College Park
Johns Hopkins University
AwardsElected to the National Academy of Medicine
Scientific career
Institutions University of Maryland School of Medicine
University of Washington School of Medicine

Kathleen Maletic Neuzil is the Director of the Center for Vaccine Development at the University of Maryland School of Medicine. She was elected to the National Academy of Medicine in 2019.

Contents

Early life and education

Neuzil studied zoology at the University of Maryland, College Park and graduated summa cum laude in 1983. [1] She was a medical student at Johns Hopkins University, where she was a member of Alpha Omega Alpha. She completed her residency at Vanderbilt University, where she specialised in internal medicine in 1987. [1] She was made a Fellow in infectious disease at Vanderbilt University in 1991. [1] After completing her fellowship, Neuzil started a Master of public health and graduated in 1998. [1]

Research and career

Neuzil works on vaccine development and policy. [2] After her fellowship Neuzil joined the University of Washington School of Medicine, where she served as Director of PATH's Influenza Vaccine Development Project. [3] [4] PATH is a Seattle-based nonprofit global health organisation, where Neuzil worked on the rotavirus, human papillomavirus infection (HPV) and Japanese encephalitis vaccines. [5] [6] In 2008 Neuzil partnered with Lentigen Corporation to research the pandemic influenza vaccine. [3] Their early work considered the development of Influenza A virus subtype H1N1 and H5N1 virus-like particle pandemic influenza vaccines. [3] Virus-like particle vaccines offer immunogenic, strain-specific recombinant antigens that can be produced at scale. [3] In 2008 Neuzil was made Chair of the Infectious Diseases Society of America Pandemic Influenza Task Force. [1] In 2015 Neuzil joined the University of Maryland School of Medicine. [4] [7]

At the Center for Vaccine Development Neuzil has developed and deployed vaccines to protect against a range of diseases including typhoid fever, shigellosis, malaria and cholera. [5] [8] She has also considered emerging pathogens such as the Zika and Ebola viruses. [5] [9] [10] The center is also part of the Typhoid Vaccine Acceleration Consortium (TyVAC), [11] a collaboration between the Oxford Vaccine Group, University of Maryland School of Medicine Center for Vaccine Development. [12] The typhoid conjugate vaccine created by TyVAC was demonstrated as a cost-effective strategy to protect people in low- and middle-income countries from typhoid. [13] In 2018 phase 2 clinical trials began on the Influenza A virus subtype H7N9 vaccine. [14]

In 2019 Neuzil and the Center for Vaccine Development at the University of Maryland School of Medicine announced a seven-year $200 million contract with the National Institute of Allergy and Infectious Diseases. [15] The research program tests seasonal influenza vaccines and features clinical trials with populations including pregnant women, children and the elderly. [5] She has spoken about the need for the public to have an influenza vaccine (flu shot), ideally by the end of October. [16] [17] [18] [19]

Alongside her academic positions, Neuzil serves on the World Health Organization Strategic Advisory Group of Experts on Immunization (SAGE) and previously on the advisory group of the Centers for Disease Control and Prevention (CDC). [5] Dr. Neuzil is central to the domestic and global response to COVID. As a Co-PI of the NIH-funded Leadership Group for the Vaccine & Treatment Evaluation Unit Network, Dr. Neuzil is part of the strategic team evaluating COVID vaccines and therapeutics in the US.

Awards and honours

Her awards and honours include;

Selected publications

a. Zaman K, Sack DA, Neuzil KM, Yunus M, Moulton LH, Sugimoto JD, Fleming JA, Hossain I, Arifeen SE, Azim T, Rahman M, Lewis KDC, Feller AJ, Qadri F, Halloran ME, Cravioto A, Victor JC. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster-randomized trial. PLoS Med. 2017 Apr;14(4):e1002282. PubMed PMID: 28419095; PubMed Central PMCID: PMC5395158.

b. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, Levine MM, Lewis K, Coia ML, Attah-Poku M, Ojwando J, Rivers SB, Victor JC, Nyambane G, Hodgson A, Schödel F, Ciarlet M, Neuzil KM. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Aug 21;376(9741):606-14. PubMed PMID: 20692030.

c. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, Han HH, Neuzil KM. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010 Jan 28;362(4):289-98. PubMed PMID: 20107214.

d. Steele AD, Patel M, Parashar UD, Victor JC, Aguado T, Neuzil KM. Rotavirus vaccines for infants in developing countries in Africa and Asia: considerations from a World Health Organization-sponsored consultation. J Infect Dis. 2009;200 Suppl 1: S63-9.

e. Patel PD, Patel P, Liang Y, Meiring JE, Misiri T, Mwakiseghile F, Tracy JK, Masesa C, Msuku H, Banda D, Mbewe M, Henrion M, Adetunji F, Simiyu K, Rotrosen E, Birkhold M, Nampota N, Nyirenda OM, Kotloff K, Gmeiner M, Dube Q, Kawalazira G, Laurens MB, Heyderman RS, Gordon MA, Neuzil KM; TyVAC Malawi Team. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children. N Engl J Med. 2021 Sep 16;385(12):1104-1115. doi: 10.1056/NEJMoa2035916. PMID: 34525285; PMCID: PMC8202713.

f. Birkhold, M., Coulibaly, Y., Coulibaly, O., Dembele, P., Kim, D., Sow, S., Neuzil KM, Morbidity and Mortality of Typhoid Intestinal Perforation Among Children in Sub-Saharan Africa 1995–2019: A Scoping Review. World J Surg (2020). May 19, 2020. https://doi.org/10.1007/s00268-020-05567-2

g. Qadri F, Khanam F, Liu X, Theiss-Nyland K, Biswas PK, Bhuiyan AI, Ahmmed F, Colin-Jones R, Smith N, Tonks S, Voysey M, Mujadidi YF, Mazur O, Rajib NH, Hossen MI, Ahmed SU, Khan A, Rahman N, Babu G, Greenland M, Kelly S, Ireen M, Islam K, O'Reilly P, Scherrer KS, Pitzer VE, Neuzil KM, Zaman K, Pollard AJ, Clemens JD. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet. 2021 Aug 9:S0140-6736(21)01124-7. doi: 10.1016/S0140-6736(21)01124-7. Epub ahead of print. PMID: 34384540.

h. Shakya M, Voysey M, Theiss-Nyland K, Colin-Jones R, Pant D, Adhikari A, Tonks S, Mujadidi YF, O'Reilly P, Mazur O, Kelly S, Liu X, Maharjan A, Dahal A, Haque N, Pradhan A, Shrestha S, Joshi M, Smith N, Hill J, Clarke J, Stockdale L, Jones E, Lubinda T, Bajracharya B, Dongol S, Karkey A, Baker S, Dougan G, Pitzer VE, Neuzil KM, Shrestha S, Basnyat B, Pollard AJ; TyVAC Nepal Team. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. Lancet Glob Health. 2021 Nov;9(11):e1561-e1568. doi: 10.1016/S2214-109X(21)00346-6. PMID: 34678198; PMCID: PMC8551681.

i. Deming ME, Michael NL, Robb M, Cohen MS, Neuzil KM. Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models. N Engl J Med. 2020 Sep 3;383(10):e63. PubMed PMID: 32610006.

j. Mehrotra DV, Janes HE, Fleming TR, Annunziato PW, Neuzil KM, Carpp LN, et al. Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. Ann Intern Med. 2021 Feb;174(2):221-228. doi: 10.7326/M20-6169. Epub 2020 Oct 22. PMID: 33090877; PMCID: PMC7596738.

k. Rapaka RR, Hammershaimb EA, Neuzil KM. Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines. Clin Infect Dis. 2021 Mar 6:ciab213. doi: 10.1093/cid/ciab213. Epub ahead of print. PMID: 33693552; PMCID: PMC7989512.

l. Follmann D, Fintzi J, Fay MP, Janes HE, Baden LR, El Sahly HM, Fleming TR, Mehrotra DV, Carpp LN, Juraska M, Benkeser D, Donnell D, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Luedtke A, Carone M, Nason M, Vandebosch A, Zhou H, Cho I, Gabriel E, Kublin JG, Cohen MS, Corey L, Gilbert PB, Neuzil KM. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. Ann Intern Med. 2021 Apr 13. doi: 10.7326/M20-8149. Epub ahead of print. PMID: 33844575.

m. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000 Jan 27;342(4):225-31. PubMed PMID: 10648763.

n. Neuzil KM, Reed GW, Mitchel EF Jr, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA. 1999 Mar 10;281(10):901-7. PubMed PMID: 10078486.

o. King JC Jr, Stoddard JJ, Gaglani MJ, Moore KA, Magder L, McClure E, Rubin JD, Englund JA, Neuzil K. Effectiveness of school-based influenza vaccination. N Engl J Med. 2006 Dec 14;355(24):2523-32. PubMed PMID: 17167135.

p. Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics. 2005 Apr;115(4):1039-47. PubMed PMID: 15805382.

q. Lewis KDC, Ortiz JR, Rahman MZ, Levine MZ, Rudenko L, Wright PF, Katz JM, Dally L, Rahman M, Isakova-Sivak I, Ilyushina NA, Matyushenko V, Fry AM, Lindstrom SE, Bresee JS, Brooks WA, Neuzil KM. Immunogenicity and Viral Shedding of Russian-Backbone, Seasonal, Trivalent, Live, Attenuated Influenza Vaccine in a Phase II, Randomized, Placebo-Controlled Trial Among Preschool-Aged Children in Urban Bangladesh. Clin Infect Dis. 2019 Aug 16;69(5):777-785. PubMed PMID: 30481272; PubMed Central PMCID: PMC6695509.

r. Diallo A, Victor JC, Feser J, Ortiz JR, Kanesa-Thasan N, Ndiaye M, Diarra B, Cheikh S, Diene D, Ndiaye T, Ndiaye A, Lafond KE, Widdowson MA, Neuzil KM. Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal. Vaccine. 2018 Oct 15;36(43):6424-6432. PubMed PMID: 30224199; PubMed Central PMCID: PMC6327321.

s. Brooks WA, Zaman K, Lewis KD, Ortiz JR, Goswami D, Feser J, Sharmeen AT, Nahar K, Rahman M, Rahman MZ, Barin B, Yunus M, Fry AM, Bresee J, Azim T, Neuzil KM. Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 2016 Dec;4(12):e946-e954. PubMed PMID: 27746226; PubMed Central PMCID: PMC5118223.

t. Victor JC, Lewis KD, Diallo A, Niang MN, Diarra B, Dia N, Ortiz JR, Widdowson MA, Feser J, Hoagland R, Emery SL, Lafond KE, Neuzil KM. Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 2016 Dec;4(12):e955-e965. PubMed PMID: 27746224; PubMed Central PMCID: PMC5118222.

Personal life

Neuzil is married with three children. [23]

Related Research Articles

<i>Rotavirus</i> Specific genus of RNA viruses

Rotavirus is a genus of double-stranded RNA viruses in the family Reoviridae. Rotaviruses are the most common cause of diarrhoeal disease among infants and young children. Nearly every child in the world is infected with a rotavirus at least once by the age of five. Immunity develops with each infection, so subsequent infections are less severe. Adults are rarely affected. There are nine species of the genus, referred to as A, B, C, D, F, G, H, I and J. Rotavirus A, the most common species, causes more than 90% of rotavirus infections in humans.

This is a timeline of the development of prophylactic human vaccines. Early vaccines may be listed by the first year of development or testing, but later entries usually show the year the vaccine finished trials and became available on the market. Although vaccines exist for the diseases listed below, only smallpox has been eliminated worldwide. The other vaccine-preventable illnesses continue to cause millions of deaths each year. Currently, polio and measles are the targets of active worldwide eradication campaigns.

<span class="mw-page-title-main">Influenza vaccine</span> Vaccine against influenza

Influenza vaccines, colloquially known as flu shots, are vaccines that protect against infection by influenza viruses. New versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. While their effectiveness varies from year to year, most provide modest to high protection against influenza. Vaccination against influenza began in the 1930s, with large-scale availability in the United States beginning in 1945.

<span class="mw-page-title-main">Live attenuated influenza vaccine</span> Nasal influenza vaccine

Live attenuated influenza vaccine (LAIV) is a type of influenza vaccine in the form of a nasal spray that is recommended for the prevention of influenza.

<span class="mw-page-title-main">Vaccine efficacy</span> Reduction of disease among the vaccinated comparing to the unvaccinated

Vaccine efficacy or vaccine effectiveness is the percentage reduction of disease cases in a vaccinated group of people compared to an unvaccinated group. For example, a vaccine efficacy or effectiveness of 80% indicates an 80% decrease in the number of disease cases among a group of vaccinated people compared to a group in which nobody was vaccinated. When a study is carried out using the most favorable, ideal or perfectly controlled conditions, such as those in a clinical trial, the term vaccine efficacy is used. On the other hand, when a study is carried out to show how well a vaccine works when they are used in a bigger, typical population under less-than-perfectly controlled conditions, the term vaccine effectiveness is used.

The rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. The vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of the risk of death among young children due to severe diarrhea. Immunizing babies decreases rates of disease among older people and those who have not been immunized.

<span class="mw-page-title-main">Typhoid vaccine</span> Vaccines that prevent typhoid fever

Typhoid vaccines are vaccines that prevent typhoid fever. Several types are widely available: typhoid conjugate vaccine (TCV), Ty21a and Vi capsular polysaccharide vaccine (ViPS). They are about 30 to 70% effective in the first two years, depending on the specific vaccine in question. The Vi-rEPA vaccine has been shown to be efficacious in children.

<span class="mw-page-title-main">Inactivated vaccine</span> Vaccine using a killed version of a disease pathogen

An inactivated vaccine is a vaccine consisting of virus particles, bacteria, or other pathogens that have been grown in culture and then killed to destroy disease-producing capacity. In contrast, live vaccines use pathogens that are still alive. Pathogens for inactivated vaccines are grown under controlled conditions and are killed as a means to reduce infectivity and thus prevent infection from the vaccine.

<span class="mw-page-title-main">Katherine O'Brien</span> Canadian-born pediatric physician (born 1963)

Katherine "Kate" L. O'Brien is a Canadian American pediatric infectious disease physician, epidemiologist, and vaccinologist who specializes in the areas of pneumococcal epidemiology, pneumococcal vaccine trials and impact studies, and surveillance for pneumococcal disease. She is also known as an expert in infectious diseases in American Indian populations. O’Brien is currently the Director of the World Health Organization's Department of Immunization, Vaccines and Biologicals.

<span class="mw-page-title-main">Rotaviral gastroenteritis</span> Medical condition

Rotavirus gastroenteritis is a major cause of severe diarrhoea among infants and young children globally. It is caused by rotavirus, a genus of double-stranded RNA virus in the family Reoviridae. The diarrhea tends to be watery and is frequently accompanied by fever, vomiting and abdominal pain. By the age of five, nearly every child in the world has been infected with rotavirus at least once. However, with each infection, immunity develops, and subsequent infections are less severe; adults are rarely affected. There are five species of this virus, referred to as A, B, C, D, and E. Rotavirus A, the most common, causes more than 90% of infections in humans.

<span class="mw-page-title-main">Universal flu vaccine</span> Vaccine that prevents infection from all strains of the flu

A universal flu vaccine is a flu vaccine that is effective against all influenza strains regardless of the virus sub type, antigenic drift or antigenic shift. Hence it should not require modification from year to year. As of 2021 no universal flu vaccine had been approved for general use, several were in development, and one was in clinical trial.

Gary J. Nabel is an American virologist and immunologist who is President and chief executive officer of ModeX Therapeutics in Natick, Massachusetts. He was the founding director of Vaccine Research Center at the National Institute of Allergy and Infectious Diseases.

Melita Alison Gordon is a gastroenterologist who works on invasive gut pathogens and tropical gastrointestinal disease. She leads the Malawi Liverpool Wellcome Trust Salmonella and Enterics Group. Gordon was awarded the British Society of Gastroenterology Sir Francis Avery Jones Research Medal in 2011.

<span class="mw-page-title-main">Bharat Biotech</span> Indian multinational biotechnology company and vaccine manufacturer

Mathuram Santosham is an Indian American physician who is Professor and Chair at the Johns Hopkins Bloomberg School of Public Health. Santosham is best known for his work on oral rehydration therapy and childhood vaccines, with a focus on supporting people from indigenous communities.

<span class="mw-page-title-main">Shabir Madhi</span> South African physician and professor

Shabir Ahmed Madhi, is a South African physician who is professor of vaccinology and director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit at the University of the Witwatersrand, and National Research Foundation/Department of Science and Technology Research Chair in Vaccine Preventable Diseases. In January 2021, he was appointed Dean of the Faculty of Health Sciences at the University of the Witwateratand.

Vaccine-associated enhanced respiratory disease (VAERD), or simply enhanced respiratory disease (ERD), is an adverse event where an exacerbated course of respiratory disease occurs with higher incidence in the vaccinated population than in the control group. It is a barrier against vaccine development that can lead to its failure.

Onyema Eberechukwu Ogbuagu is an American-born infectious diseases physician, educator, researcher, and clinical trial investigator, who was raised and educated in Nigeria. He is an associate professor at Yale School of Medicine in New Haven, CT and is the director of the Yale AIDS Program clinical trials unit. His research contributions have focused on HIV/AIDS prevention and COVID-19 vaccination and treatment clinical trials. He switched his focus at the beginning of the 2019 COVID pandemic and participated as a principal investigator (PI) on the Pfizer-BioNtech COVID-19 vaccine trials and the Remdesivir SIMPLE trial in 2020 and 2021. In pursuit of his global health component of his career, Ogbuagu also supports postgraduate physician medical education programs in low and middle income countries in sub-Saharan Africa in Rwanda (2013–2018) and Liberia as well as HIV treatment programs in Liberia.

Stephen L. Hoffman is an American physician-scientist, tropical medicine specialist and vaccinologist, who is the founder and chief executive and scientific officer of Sanaria Inc., a company dedicated to developing PfSPZ vaccines to prevent malaria.

Julie Bines, is a clinician and researcher working in Melbourne, Australia. Alongside being a professor and deputy head of the Department of Paediatrics at the University of Melbourne, she is also a paediatric gastroenterologist at the Royal Children's Hospital Melbourne and is the leader of the Enteric Diseases group at the Murdoch Children's Research Institute. Bines is the joint head of the WHO Collaborative Centre for Child Health and founding member of Women in Global Health Australia.

References

  1. 1 2 3 4 5 "Neuzil, Kathleen | University of Maryland School of Medicine". www.medschool.umaryland.edu. Retrieved 2019-11-08.
  2. ↑ Staff, Daily Record (2018-04-12). "Kathy Maletic Neuzil". Maryland Daily Record. Retrieved 2019-11-08.
  3. 1 2 3 4 "Lentigen and PATH announce partnership on innovative vaccine for pandemic influenza". www.path.org. Retrieved 2019-11-08.
  4. 1 2 "Kathleen M. Neuzil". Rota Council. Retrieved 2019-11-08.
  5. 1 2 3 4 5 "University of Maryland receives landmark contract to research influenza vaccines". EurekAlert!. Retrieved 2019-11-08.
  6. ↑ "Find resources - PATH Vaccine Resource Library". vaccineresources.org. Retrieved 2019-11-08.
  7. ↑ Cohn, Meredith (6 April 2015). "University of Maryland School of Medicine launches Institute for Global Health". baltimoresun.com. Retrieved 2019-11-08.
  8. ↑ "Vaccines, antimicrobial resistance, and health equity | Department of Medicine | University of Washington". medicine.uw.edu. Retrieved 2019-11-08.
  9. ↑ link.videoplatform.limelight.com http://link.videoplatform.limelight.com/media/?mediaId=c3ebe775eaa14d128dbbbe48f67afd25&width=100%25&height=100%25&playerForm= . Retrieved 2019-11-08.{{cite web}}: Missing or empty |title= (help)
  10. ↑ Cohn, Meredith (4 August 2016). "University of Maryland researchers to test new Zika vaccine". baltimoresun.com. Retrieved 2019-11-08.
  11. ↑ "About the Typhoid Vaccine Acceleration Consortium". Take on Typhoid. Retrieved 2019-11-08.
  12. ↑ "International consortium, including OVG, receives $36.9 million grant to fight Typhoid — Oxford Vaccine Group". www.ovg.ox.ac.uk. Retrieved 2019-11-08.
  13. ↑ Poitras, Colin. "Vaccine Is a Cost-effective Solution for Countries Burdened by Typhoid". Yale School of Public Health. Retrieved 2019-11-08.
  14. ↑ "H7N9 influenza vaccine clinical trials begin - EPR". European Pharmaceutical Review. Retrieved 2019-11-08.
  15. ↑ "Center for Vaccine Development Awarded up to $201M to Establish Influenza Clinical Core". globalbiodefense.com. 20 September 2019. Retrieved 2019-11-08.
  16. ↑ Sun, Christina Tkacik | The Baltimore. "With flu season on the horizon, a Q&A on this year's vaccine". www.abqjournal.com. Retrieved 2019-11-08.
  17. ↑ CVD Director Dr. Kathleen Neuzil Appears on MPT's YourHealth , retrieved 2019-11-08
  18. ↑ "Kathleen Neuzil | The Seattle Times". www.seattletimes.com. 22 May 2009. Retrieved 2019-11-08.
  19. ↑ Kathleen Neuzil, MD, MPH Gets Vaccinated against Flu to Protect Patients , retrieved 2019-11-08
  20. ↑ "Kathleen Neuzil, M.D., M.P.H." Vanderbilt University. Retrieved 2019-11-08.
  21. ↑ Staff, Daily Record (2018-03-09). "The Daily Record announces Top 100 Women honorees". Maryland Daily Record. Retrieved 2019-11-08.
  22. ↑ "UM School Of Medicine's Kathleen Neuzil elected to National Academy of Medicine". EurekAlert!. Retrieved 2019-11-08.
  23. ↑ comment, NFID in Vaccines Leave a (2019-05-12). "Sharing the Gift of Health: Happy Mother's Day". National Foundation for Infectious Diseases. Retrieved 2019-11-08.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.